After an extensive investigation, the Federal Trade Commission on Wednesday cleared Pfizer Inc.’s acquisition of Wyeth, but required divestitures in the animal pharmaceutical market.

FTC staff conducted nearly 200 interviews and reviewed hundreds of thousands of pages of documents before concluding that the deal did not raise anti-competitive concerns in any human health product markets. But the commission did find overlap for animal products such as vaccines for cattle, dogs, cats and horses.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]